

State of Oklahoma Oklahoma Health Care Authority

Xofigo® (Radium-223 Dichloride) Prior Authorization Form

| Member Name: | Date of Birth: | Member ID#: |
|--|-----------------|----------------------------|
| Drug Information | | |
| Physician billing (HCPCS code: |) Start Dat | te (or date of next dose): |
| Dose: | Regimen: | |
| Billing Provider Information | | |
| Provider NPI:Provider Name: | | |
| Provider Phone: Provider Fax: | | |
| Prescriber Information | | |
| Prescriber NPI: Prescriber Name: | | |
| Prescriber Phone: | Prescriber Fax: | Specialty: |
| Criteria | | |
| Diagnosis of metastatic, castration-resistant prostate cancer? Yes No If answer is 'no' from previous question, please indicate diagnosis: Additional Information: Dease indicate requested information: Does the member have symptomatic bone metastases? Yes No Does the member have known visceral metastatic disease? Yes No Will radium-223 (Xofigo[®]) be used in combination with chemotherapy? Yes No Please provide the following: Date taken: Member's absolute neutrophil count: Date taken: Member's hemoglobin: Date taken: | | |
| d. Member's body weight (kg): Date taken: | | |
| Prescriber Signature: Date: Date: I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. | | |

knowledge.Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will

Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at

AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.